Trials: Lymphoma

You are here:

Find a Clinical Trial
Lymphoma

Gut Microbiome in Acute Leukemia and Allogeneic Stem Cell Transplant Patients

June 24, 2026

NCT04400591 – Expanded Access Protocol (EAP) for Patients Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release

June 10, 2026

NCT04637763 – A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

June 24, 2026

NCT04637763 – A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

June 29, 2026

NCT05554406 – MM1YA-S01, “A Randomized Phase II Study Comparing Cytarabine + Daunorubicin(7+3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin +Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome+ Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk(Adverse) Acute Myeloid Leukemia as Determined by MYELOMATCH; AMyeloMATCH Clinical Trial”

June 24, 2026

NCT05564390 – MYELOMATCH, Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials

June 10, 2026

NCT05633615 – S2114: A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma

June 10, 2026

NCT06337318 – S2308 Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma

June 24, 2026

NCT06852222 – A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of BLEXIMENIB, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations who are Ineligible for Intensive Chemotherapy

June 24, 2026